Santhera Pharmaceuticals' H1 Attributable Net Loss Narrows; Revenue Rises

01:19 AM EDT, 09/30/2026 (MT Newswires) -- Santhera Pharmaceuticals (SANN.SW) on Wednesday reported a narrowed net loss for the first half, while revenue from contracts with customers rose year over year. Net loss attributable to shareholders for the six months ended June 30 was 21.5 million francs, compared with 38.8 million francs earlier. Loss per share moved to 1.50 francs from 3.04 francs. The Swiss specialty pharmaceutical company's revenue from contracts with customers was 48.3 million francs, compared with 24 million francs a year ago. For 2026, the company reiterated its total revenue guidance in the range of 80 million francs to 90 million francs. For the mid-term, Santhera revised its total revenue outlook, excluding milestones, to 140 million francs from 150 million francs in 2028, further targeting 250 million francs by 2030.